Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at

Stock analysts at began coverage on shares of Agile Therapeutics (NASDAQ:AGRXGet Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group upgraded shares of Agile Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 26th.

Agile Therapeutics Stock Performance

Shares of NASDAQ AGRX opened at $0.53 on Wednesday. Agile Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $50.40. The company has a market cap of $2.42 million, a price-to-earnings ratio of -0.02 and a beta of 1.23. The business’s 50 day moving average price is $0.99 and its 200-day moving average price is $6.86.

Agile Therapeutics (NASDAQ:AGRXGet Rating) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) earnings per share for the quarter. The business had revenue of $1.76 million during the quarter. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. Sell-side analysts predict that Agile Therapeutics will post -2.19 earnings per share for the current year.

Institutional Investors Weigh In On Agile Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AGRX. Perceptive Advisors LLC grew its position in shares of Agile Therapeutics by 33.8% during the 4th quarter. Perceptive Advisors LLC now owns 21,294,485 shares of the specialty pharmaceutical company’s stock worth $10,394,000 after buying an additional 5,374,560 shares in the last quarter. BlackRock Inc. lifted its stake in Agile Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock worth $319,000 after acquiring an additional 16,104 shares during the period. GSA Capital Partners LLP grew its holdings in Agile Therapeutics by 25.1% during the 4th quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company’s stock worth $358,000 after acquiring an additional 147,194 shares in the last quarter. Renaissance Technologies LLC increased its position in Agile Therapeutics by 281.3% during the 1st quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares during the period. Finally, First Citizens Bank & Trust Co. bought a new stake in shares of Agile Therapeutics in the 1st quarter valued at about $42,000. 27.96% of the stock is owned by institutional investors.

About Agile Therapeutics

(Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.